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Background
Despite  signiﬁcant  progress  in  the  past  decade  in  our  understanding  of  the  molecular  path-
ways  involved  in  the  atherosclerotic  cascade,  cardiovascular  disease  due  to  atherosclerosis
remains  the  leading  cause  of  mortality  and  major  morbidity  in  developed  countries.  To
control  the  rising  costs  of  healthcare,  the  current  focus  of  cardiovascular  medicine  is  to
identify  critical  cellular  and  molecular  mechanisms  of  atherosclerotic  disease,  in  order  to
develop  novel  preventive  and  therapeutic  strategies  [1].  For  example,  our  understanding
of  the  role  of  cholesterol  metabolism  and  low-density  lipoproteins  as  cardiovascular  risk
factors  has  led  to  considerable  therapeutic  advances,  primarily  with  the  development  of
statins.  However,  two  out  of  three  patients  treated  with  statins  still  present  with  a  major
coronary  event,  which  presents  a  signiﬁcant  residual  burden  of  cardiovascular  risk  [2].
From the atherosclerotic plaque to the clinical event
For  a  long  time  it  was  believed  that  most  cases  of  acute  atherosclerotic  events  would  arise
from  advanced  atherosclerotic  disease  causing  severe  arterial  stenosis.  More  recent  studies
instead  suggest  that  the  lesions  responsible  for  sudden  clinical  events  are  frequently  angio-
graphically  mild  [3].  These  ﬁndings  may  explain  why  patients  without  symptomatic  disease
are  not  free  from  residual  risk.  In  fact,  a  large  number  of  fatalities  due  to  atherosclerosis
occur  in  apparently  healthy  individuals,  who  die  suddenly  without  prior  symptoms.
Abbreviations: CT, Computed tomography; MRI, Magnetic resonance imaging; PET, Positron emission tomography; SPECT, Single-photon
emission computed tomography.
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he challenge of identifying
therosclerosis
lmost  20  years  ago,  some  authors  highlighted  that  the
hallenge  for  the  future  would  be  to  develop  non-invasive
creening  methods  of  detecting  atherosclerosis  in  its  earliest
tages  [4].  If  circulating  biomarkers  and  genetic  assessment
an  help  to  identify  high-risk  patients  within  the  general
opulation,  imaging  techniques  give  the  opportunity  to  iden-
ify  and  evaluate  the  burden  of  atherosclerotic  disease  in
uch  patients.  Computed  tomography  (CT)  and  magnetic
esonance  angiography  can  identify  advanced  atheroscle-
otic  lesions  by  quantifying  luminal  stenosis.  Additionally,
T  and  magnetic  resonance  imaging  (MRI)  can  also  quantify
therosclerotic  burden  in  non-stenotic  lesions  and  charac-
erize  plaque  composition  in  terms  of  lipids,  ﬁbrous  tissue
alciﬁcation  and  microvasculature  [5,6].  However,  if  the
orphological  approach  of  these  techniques  can  eliminate
he  risk  by  excluding  the  presence  of  atherosclerotic  plaque,
t  is  still  limited  in  terms  of  predicting  cardiovascular  events
7].  Indeed,  major  adverse  cardiovascular  events  are  most
ommonly  caused  by  thrombotic  occlusion  of  a  high-risk
oronary  plaque.  High-risk  atherosclerotic  plaque  —  or  vul-
erable  plaque  —  represents  the  susceptibility  of  a  plaque
o  rupture  [8]  and  its  detection  has  become  the  goal  of  new
maging  techniques.  The  morphological  approach  does  not
rovide  information  regarding  functional  variables,  such  as
laque  metabolism  and  inﬂammation,  which  are  recognized
arkers  of  vulnerability.
therosclerotic molecular imaging
olecular  imaging  is  deﬁned  as  the  in  vivo  characterization
nd  measurement  of  biological  processes  at  the  cellular,
olecular,  whole  organ  or  body  level  [9].  In  addition  to
roviding  anatomical  information,  molecular  imaging  tech-
iques  can  quantify  speciﬁc  biological  processes,  thus  giving
nsight  into  the  functional  parameters  of  tissues.  These
ay  prove  useful  not  only  for  detecting  subclinical  disease
efore  anatomical  changes  in  plaque  size  occur,  but  also  for
ssessing  the  effect  of  approved  and  novel  treatments,  while
mproving  our  understanding  of  the  biology  of  atherosclero-
is.
Inﬂammation  is  currently  regarded  as  one  of  the  func-
ional  features  of  vulnerable  plaques,  and  is  therefore  an
ttractive  target  for  molecular  imaging  techniques  [10],
o  measure  disease  progression  and,  potentially,  the  risk
f  rupture.  Some  of  the  key  steps  involved  in  the  inﬂam-
atory  cascade  are  endothelial  dysfunction,  expression  of
ellular  adhesion  molecules,  lipid  retention,  macrophage
ctivation,  apoptosis,  proteolysis  and  neoangiogenesis,  all
f  which  can  be  targeted  using  molecular  imaging  [11].
uantiﬁcation  of  these  features  has  been  possible  thanks
o  the  development  of  high-resolution,  high-sensitivity  mul-
imodal  imaging  systems,  which  can  quantify  the  uptake  in
therosclerotic  plaques  of  tracers  targeted  to  speciﬁc  bio-
ogical  processes.  These  include  ultrasound,  single-photon
mission  CT  (SPECT),  positron  emission  tomography  (PET),
T,  MRI  and  optical  techniques,  including  ﬂuorescence-
ediated  tomography  and  catheter-based  sensors  [12].  The
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peciﬁcity  of  these  techniques  depends  on  the  selectivity
f  the  tracer  employed,  while  sensitivity  depends  on  the
ntrinsic  capabilities  and  limitations  of  each  modality.  For
xample,  optical  imaging  techniques  allow  high-speciﬁcity
y  using  a  customized  probe  for  every  target  of  interest.  Cur-
ently,  these  techniques  are  mainly  conﬁned  to  research,  but
heir  application  is  rapidly  expanding  in  the  medical  ﬁeld
13]. Ultrasound  has  the  advantage  of  being  non-invasive,
on-ionizing  and  relatively  inexpensive,  which  makes  it  a
idely  available  technique.  However,  the  limited  penetra-
ion  depth  and  the  lack  of  speciﬁc  molecular  probes  limit  its
se  in  molecular  imaging.  MRI  and  CT  are  widely  available
echniques  that  share  the  advantage  of  superior  spatial  res-
lution  compared  with  other  modalities;  both  can  be  used
lone  or  in  combination,  with  either  non-targeted  or  tar-
eted  contrast  agents,  to  better  quantify  the  features  of
laque  vulnerability  [14]. Both  radionuclide  imaging  tech-
iques  —  SPECT  and  PET  —  have  the  advantage  of  being
on-invasive  with  high  sensitivity  and  speciﬁcity,  which
akes  them  particularly  suited  for  molecular  imaging  of
therosclerosis  [9].  In  addition  to  exposure  to  ionizing  radi-
tion,  they  have  the  disadvantage  of  low  spatial  resolution
nd  often  require  advanced  radiochemistry  techniques  if
peciﬁc  tracers  have  to  be  used  [9]. To  exploit  the  advan-
ages  of  different  techniques  at  once,  the  current  trend
s  to  develop  multimodality  imaging  systems  that  integrate
olecular,  physiological  and  anatomical  information  [11].
or  example,  the  high  sensitivity  of  nuclear  techniques  can
e  coupled  with  the  high  spatial  resolution  of  CT  or  MRI  in
ultimodality  hybrid  systems  such  as  SPECT/CT,  PET/CT  or
RI/PET  [12]  for  superior  disease  characterization.
imits of atherosclerotic molecular
maging
espite  the  exponential  development  of  molecular  imag-
ng  probes  and  systems  in  recent  years,  the  translation
f  this  concept  into  clinical  applications  is  lagging  behind
12]. Atherosclerotic  molecular  imaging  has  the  potential  to
mage  the  pathophysiological  process  of  the  disease  before
he  onset  of  symptoms,  thereby  creating  the  possibility  of
dentifying  new  therapies  and  speciﬁcally  identifying  the
ubpopulations  of  patients  who  will  most  likely  respond  to
uch  therapies.  These  diagnostic  techniques  will  allow  a  bet-
er  understanding  of  the  pathophysiology  of  disease,  leading
o  the  development  of  novel  strategies  for  intervention.
owever,  the  high  costs  associated  with  the  development
nd  validation  of  these  techniques  in  a  clinical  setting,  as
ell  as  some  potential  safety  considerations,  have  signiﬁ-
antly  reduced  their  translational  impact  so  far.
onclusion
therosclerotic  molecular  imaging  is  a  promising  non-
nvasive  tool  for  detecting  the  vulnerable  plaque  and
onsequently  the  vulnerable  patient.  Molecular  imaging
oes  not  focus  solely  on  detection  of  subclinical  disease,
ut  also  improves  our  understanding  of  the  biology  of
therosclerosis,  leading  to  early  evaluation  of  the  effects  of
rug  intervention.  Understanding  and  identifying  the  steps
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of  atherosclerotic  disease  opens  the  ﬁeld  of  development
of  pharmacological  and  mechanical  strategies  to  prevent
cardiovascular  morbidity  and  mortality.
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